Press Releases

San Francisco, California, USA, January 9, 2023 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global CRDMO service company, announced today that it will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Chris Chen Ph.D., CEO of WuXi Biologics, will present the keynote of “Global Premier CRDMO: Enabling Global Partners and Delivering Sustainable High Growth” on January 10 at 9:00am-9:40am PST.

A live audio steam will be available on the website: https://jpmorgan.metameetings.net/events/healthcare24/sessions/49344-wuxi-biologics/webcast?gpu_only=true&kiosk=true

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2023, WuXi Biologics is supporting 621 integrated client projects, including 22 in commercial manufacturing.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

Business

info@wuxibiologics.com

Media:

PR@wuxibiolgics.com